Form 4: FRACTYL HEALTH CEO Granted 2.48M Stock Options

FRACTYL HEALTH, INC. CEO Harith Rajagopalan was granted 2,486,302 stock options with an exercise price of $2.24, vesting over three years.

Summary

• Harith Rajagopalan, Chief Executive Officer and Director of FRACTYL HEALTH, INC. (GUTS), was granted 2,486,302 stock options.
• The transaction date for this grant was December 15, 2025.
• Each stock option has an exercise price of $2.24.
• The options will vest in equal installments on each of the first three anniversaries of the grant date, contingent on Mr. Rajagopalan's continued employment.
• The expiration date for these stock options is December 14, 2035.
• Following this transaction, Mr. Rajagopalan beneficially owns 2,486,302 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is a positive for aligning management incentives with long-term shareholder value, reflecting standard executive compensation practices. It does not introduce new negative information about the company's operations or financial health.

Positives

• The grant of stock options to the Chief Executive Officer aligns management's long-term incentives with shareholder value, encouraging sustained performance.
• The vesting schedule over three years promotes executive retention and a focus on long-term strategic goals.

Risks

• The value of the stock options is directly tied to the future performance of FRACTYL HEALTH, INC.'s common stock, meaning the options could become worthless if the stock price does not exceed the exercise price.
• The vesting of the options is subject to the Reporting Person's continuing employment through each vesting date, posing a personal risk to the CEO if employment ceases.

Future Outlook

The grant of stock options with a multi-year vesting schedule indicates a long-term incentive structure for the CEO, aligning their future compensation with the company's sustained performance over the next three years and beyond, up to the option's expiration in 2035.

Industry Context

The grant of stock options to a Chief Executive Officer is a standard and widely adopted practice in the biotechnology and healthcare technology sectors. It serves as a key component of executive compensation packages, designed to attract, retain, and motivate top talent by linking their personal financial success to the long-term growth and stock performance of the company. This practice is consistent with compensation strategies observed across comparable companies in the industry.

Comparison to Industry Standards

• The use of stock options as a primary incentive for a CEO is a common practice across the biotech and health tech industries, similar to companies like Moderna, BioNTech, or other early-stage medical device/therapy developers.
• A three-year vesting schedule is typical for executive equity grants, providing a balance between immediate incentive and long-term commitment, comparable to structures seen at companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals for their executive teams.
• The size of the grant (2.48 million options) would need to be assessed against the company's total outstanding shares and market capitalization to determine its relative scale compared to peer grants, but without that context, it appears to be a substantial grant for a CEO.

Corporate Governance

Related Party Transactions

• The grant of stock options to Harith Rajagopalan, the Chief Executive Officer and a Director, constitutes a related party transaction as it involves compensation provided by the company to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to enhanced alignment of CEO's interests with long-term shareholder value through equity incentives.
• Employees (CEO): Direct financial benefit and long-term incentive tied to company performance and continued employment.

Next Steps

• The stock options will vest in equal installments on the first three anniversaries of the grant date (December 15, 2025), subject to the CEO's continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine stock option grant to the CEO, which is a standard executive compensation practice. It does not provide new information that would significantly alter the fundamental investment thesis for FRACTYL HEALTH, INC., thus a 'hold' recommendation is maintained based solely on this disclosure. Investors should consider broader company fundamentals and market conditions for a comprehensive investment decision.

Keywords

FRACTYL HEALTH, GUTS, Stock Option, Harith Rajagopalan, CEO, Executive Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotech